GURUFOCUS.COM » STOCK LIST » USA » NYSE » Boston Scientific Corp (NYSE:BSX) » Definitions » Debt-to-EBITDA
Switch to:

Boston Scientific Debt-to-EBITDA

: 3.37 (As of Jun. 2022)
View and export this data going back to 1992. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Boston Scientific's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $170 Mil. Boston Scientific's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $9,157 Mil. Boston Scientific's annualized EBITDA for the quarter that ended in Jun. 2022 was $2,772 Mil. Boston Scientific's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 was 3.36.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Boston Scientific's Debt-to-EBITDA or its related term are showing as below:

BSX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.35   Med: 4.58   Max: 14.09
Current: 3.41

During the past 13 years, the highest Debt-to-EBITDA Ratio of Boston Scientific was 14.09. The lowest was -1.35. And the median was 4.58.

BSX's Debt-to-EBITDA is ranked worse than
78.02% of 414 companies
in the Medical Devices & Instruments industry
Industry Median: 1.05 vs BSX: 3.41

Boston Scientific Debt-to-EBITDA Historical Data

The historical data trend for Boston Scientific's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boston Scientific Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Debt-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.78 2.75 4.73 6.79 3.77

Boston Scientific Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.75 2.81 4.76 3.41 3.37

Competitive Comparison

For the Medical Devices subindustry, Boston Scientific's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Boston Scientific Debt-to-EBITDA Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Boston Scientific's Debt-to-EBITDA falls into.



Boston Scientific Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Boston Scientific's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(261 + 9190) / 2510
=3.77

Boston Scientific's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(170 + 9157) / 2772
=3.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2022) EBITDA data.


Boston Scientific  (NYSE:BSX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Boston Scientific Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Boston Scientific's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Boston Scientific Business Description

Boston Scientific logo
Address
300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Executives
Wichmann David S director UNITEDHEALTH GROUP INC 9900 BREN RD E MINNETONKA MN 55343
Brown Vance R officer: SVP, GC and Corp. Secretary C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752
Olson Scott officer: SVP & Pres, Rhythm Management C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752
Scanlon Meghan officer: SVP,Pres,Urology Pelvic Health C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752
Monson Jonathan officer: VP, Corp Controller and CAO C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752
Fujimori Yoshiaki director 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752
James Donna director ONE MIRANOVA PLACE SUITE 1040 COLUMBUS OH 43215
Zane Ellen M director C/O TUFTS-NEW ENGLAND MEDICAL CENTER 750 WASHINGTON STREET, TUFTS-NEMC #451 BOSTON MA 02111
Sununu John E director C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752
Connors Nelda J director BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234
Ludwig Edward J director C/O BECTON DICKERSON & CO 1 BECTON DR FRANKLIN LAKES NJ 07417
Roux David J director C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752
Dockendorff Charles J director COVIDIEN LTD. 15 HAMPSHIRE STREET MANSFIELD MA 02048
Macmillan Stephen P director 250 CAMPUS DRIVE MARLBOROUGH MA 01752
Wang Xin Warren officer: SVP and Pres, Asia Pacific C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752

Boston Scientific Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)